Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. IMVT-1401 is in Phase IIa clinical trials for the. treatment of myasthenia gravis and thyroid eye disease. The company is headquartered in New York, New York.
Market Cap | 2.018 Billion | Shares Outstanding | 129.182 Million | Avg 30-day Volume | 886.626 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.49 |
Price to Revenue | 0.0 | Debt to Equity | 0.0 | EBITDA | -156.688 Million |
Price to Book Value | 1.2863 | Operating Margin | 0.0 | Enterprise Value | 110.516 Million |
Current Ratio | 11.521 | EPS Growth | 0 | Quick Ratio | 11.367 |
1 Yr BETA | 1.1324 | 52-week High/Low | 20.24 / 3.15 | Profit Margin | 0.0 |
Operating Cash Flow Growth | 0.0 | Altman Z-Score | 7.0491 | Free Cash Flow to Firm | 0 |
Earnings Report | 2023-06-07 |
Please sign in first
none
10.7 Thousand total shares from 2 transactions
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
MACIAS WILLIAM L. CHIEF MEDICAL OFFICER |
|
262,996 | 2023-02-02 | 6 |
LEVINE MARK S. CHIEF LEGAL OFFICER |
|
245,660 | 2023-01-26 | 2 |
BUTCHKO JULIA G. CHIEF DEV. & TECH. OFFICER |
|
331,419 | 2023-01-11 | 9 |
SALZMANN PETER CHIEF EXECUTIVE OFFICER |
|
993,932 | 2023-01-11 | 9 |
BARNETT EVA RENEE CHIEF FINANCIAL OFFICER |
|
268,347 | 2023-01-11 | 3 |
|
73,805,331 | 2022-10-06 | 1 | |
|
102,985 | 2022-09-30 | 2 | |
|
393,358 | 2022-09-29 | 2 | |
|
109,985 | 2022-08-17 | 1 | |
|
88,485 | 2022-08-17 | 1 | |
|
101,232 | 2022-08-17 | 1 | |
JAIN RITA CHIEF MEDICAL OFFICER |
|
129,365 | 2021-03-19 | 0 |
YANCHIK CONNEALY PAMELA CHIEF FINANCIAL OFFICER |
|
46,200 | 2021-03-19 | 0 |
ELLIOTT MICHAEL JAMES CHIEF SCIENTIFIC OFFICER |
|
97,600 | 2021-03-19 | 0 |
WONG RODERICK CHIEF EXECUTIVE OFFICER |
|
902,498 | 2019-12-11 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-02-03 07:24:19 -0500 | 2023-02-02 | S | 537 | $18.24 | d | 262,996 | direct | 3.7183 | 3.831 | -5.9155 | 7.0423 | 3 | -13.9155 | 29 | ||
2023-01-27 07:20:19 -0500 | 2023-01-26 | S | 10,156 | $18.51 | d | 245,660 | direct | -2.6524 | 0.1693 | -10.8352 | 7.2235 | 8 | -12.246 | 30 |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
IMMUNOVANT INC IMVT | 2023-03-24 22:15:03 UTC | 4.5256 | 0.2944 | 600000 |
IMMUNOVANT INC IMVT | 2023-03-24 21:45:03 UTC | 4.5256 | 0.2944 | 600000 |
IMMUNOVANT INC IMVT | 2023-03-24 21:15:03 UTC | 4.5256 | 0.2944 | 600000 |
IMMUNOVANT INC IMVT | 2023-03-24 20:45:03 UTC | 4.4446 | 0.3754 | 600000 |
IMMUNOVANT INC IMVT | 2023-03-24 20:15:04 UTC | 4.4446 | 0.3754 | 600000 |
IMMUNOVANT INC IMVT | 2023-03-24 19:45:03 UTC | 4.4446 | 0.3754 | 600000 |
IMMUNOVANT INC IMVT | 2023-03-24 19:15:04 UTC | 4.4446 | 0.3754 | 600000 |
IMMUNOVANT INC IMVT | 2023-03-24 18:45:04 UTC | 4.4446 | 0.3754 | 600000 |
IMMUNOVANT INC IMVT | 2023-03-24 18:15:03 UTC | 4.4446 | 0.3754 | 600000 |
IMMUNOVANT INC IMVT | 2023-03-24 17:45:03 UTC | 4.4446 | 0.3754 | 600000 |
IMMUNOVANT INC IMVT | 2023-03-24 17:15:03 UTC | 4.4446 | 0.3754 | 600000 |
IMMUNOVANT INC IMVT | 2023-03-24 16:45:03 UTC | 4.4446 | 0.3754 | 600000 |
IMMUNOVANT INC IMVT | 2023-03-24 16:15:03 UTC | 4.4446 | 0.3754 | 550000 |
IMMUNOVANT INC IMVT | 2023-03-24 15:45:03 UTC | 4.4446 | 0.3754 | 550000 |
IMMUNOVANT INC IMVT | 2023-03-24 15:15:03 UTC | 4.4446 | 0.3754 | 600000 |
IMMUNOVANT INC IMVT | 2023-03-24 14:45:03 UTC | 4.4446 | 0.3754 | 650000 |
IMMUNOVANT INC IMVT | 2023-03-24 14:15:03 UTC | 4.4446 | 0.3754 | 550000 |
IMMUNOVANT INC IMVT | 2023-03-24 13:45:03 UTC | 4.2659 | 0.3041 | 550000 |
IMMUNOVANT INC IMVT | 2023-03-24 13:15:04 UTC | 4.2659 | 0.3041 | 550000 |
IMMUNOVANT INC IMVT | 2023-03-24 12:45:03 UTC | 4.2659 | 0.3041 | 600000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
RUSSELL INVESTMENT CO- U.S. Small Cap Equity Fund | IMVT | -4656.0 shares, $-52147.2 | 2022-10-31 | N-PORT |
RUSSELL INVESTMENT FUNDS- U.S. Small Cap Equity Fund | IMVT | -1236.0 shares, $-21939.0 | 2022-12-31 | N-PORT |